Frontiers | EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers
Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2–EED Interaction | Journal of Medicinal Chemistry
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial - The Lancet Haematology
Enhancer Of Zeste Homolog 2 EZH2 Inhibitor Market Clinical Trials Insight Report 2026
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer | Nature Cancer
Pre-clinical studies of EZH2 inhibitors in MM | Download Table
Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors | Clinical Epigenetics | Full Text
Known EZH2 inhibitors. GSK126, tazemetostat and CPI-1205 are in... | Download Scientific Diagram
Clinical studies involving EZH2 inhibitors in haematological neoplasms | Download Table
Global EZH2 Inhibitor Market Opportunity, Sales & Clinical Trials Insight 2026
Histone-writer cancer drugs enter center stage | Nature Biotechnology
EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies | Biomarker Research | Full Text
Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation | Nature Communications
Current clinical trials for EZH2 inhibitors. | Download Table
Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer - ScienceDirect
Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis | Cell Death Discovery
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition: Trends in Immunology
Clinical studies involving EZH2 inhibitors in haematological neoplasms | Download Table
Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype | Clinical Epigenetics | Full Text
Frontiers | Easy or Not—The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity
Current clinical trials for EZH2 inhibitors. | Download Table
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study - The Lancet Oncology
IJMS | Free Full-Text | EZH2 as a Potential Target for NAFLD Therapy | HTML
EZH2: a novel target for cancer treatment | Journal of Hematology & Oncology | Full Text
Inhibition of EZH2 (Enhancer of Zeste Homolog 2) Attenuates Neuroinflammation via H3k27me3/SOCS3/TRAF6/NF-κB (Trimethylation of Histone 3 Lysine 27/Suppressor of Cytokine Signaling 3/Tumor Necrosis Factor Receptor Family 6/Nuclear Factor-κB) in a Rat Model
